Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peregrine Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female at least 18 years of age
Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)
Radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate hematologic, renal and hepatic function
You may not be if
Squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell NSCLC
Known history of bleeding disorders, eg, von Willebrand disease or hemophilia
Cavitary tumors or tumors invading or abutting large blood vessels
Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening
Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening
Grade 2 or higher peripheral neuropathy
Clareo Health | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
